Agios Pharmaceuticals, Inc.
AGIOFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Agios Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 15 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 23, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Qube Research & Technologies Ltd | 2026-03-31 | 187,667 | $6.35M | SEC filing |
| MARTINGALE ASSET MANAGEMENT L P | 2026-03-31 | 35,814 | $1.21M | SEC filing |
| Lynx1 Capital Management LP | 2026-03-31 | 2,611,568 | $88.3M | SEC filing |
| FMR LLC | 2026-03-31 | 9,121 | $309K | SEC filing |
| INTECH INVESTMENT MANAGEMENT LLC | 2026-03-31 | 14,029 | $475K | SEC filing |
| NOMURA HOLDINGS INC | 2026-03-31 | 9,176 | $310K | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 186,791 | $6.32M | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 61,494 | $1.67M | SEC filing |
| UBS Group AG | 2026-03-31 | 132,540 | $4.48M | SEC filing |
| Vestal Point Capital, LP | 2026-03-31 | 450,000 | $15.2M | SEC filing |
| Fiduciary Trust Co | 2026-03-31 | 8,247 | $279K | SEC filing |
| Parkside Financial Bank & Trust | 2026-03-31 | 62 | $2.1K | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 4,044 | $119K | SEC filing |
| RHUMBLINE ADVISERS | 2026-03-31 | 73,369 | $2.48M | SEC filing |
| Keating Financial Advisory Services, Inc. | 2026-03-31 | 143 | $4.84K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 967,525 | $32.7M | SEC filing |
| Creative Planning | 2026-03-31 | 13,333 | $451K | SEC filing |
| SEI INVESTMENTS CO | 2026-03-31 | 63,550 | $2.15M | SEC filing |
| Essential Partners LLC | 2026-03-31 | 5 | $169 | SEC filing |
| Police & Firemen's Retirement System of New Jersey | 2026-03-31 | 15,640 | $529K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Agios Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-02 · Goff Brian: Larger than 51 of the 52 other insider sales of Common stock on file. SEC filing
- 2025-12-30 · Goff Brian: Larger than all 52 other insider sales of Common stock on file. SEC filing
- 2025-09-05 · Washburn Theodore James Jr.: Larger than 47 of the 52 other insider sales of Common stock on file. SEC filing
- 2025-08-08 · Goff Brian: Larger than 49 of the 52 other insider sales of Common stock on file. SEC filing
- 2025-07-09 · Gheuens Sarah: Larger than 48 of the 52 other insider sales of Common stock on file. SEC filing
- 2025-06-24 · Goff Brian: Larger than 50 of the 52 other insider sales of Common stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-02 | Goff Brian · Chief Executive Officer | Common stock | S — Open market or private sale | −12,472 | 34.71 | SEC filing |
| 2026-04-02 | Jones Cecilia · Chief Financial Officer | Common stock | S — Open market or private sale | −3,141 | 34.71 | SEC filing |
| 2026-04-02 | Gheuens Sarah · Chief Medical Officer | Common stock | S — Open market or private sale | −2,940 | 34.71 | SEC filing |
| 2026-04-02 | Goff Brian · Chief Executive Officer | Common stock | S — Open market or private sale | −6,596 | 34.71 | SEC filing |
| 2026-04-02 | Milanova Tsveta · Chief Commercial Officer | Common stock | S — Open market or private sale | −3,262 | 34.71 | SEC filing |
| 2026-04-02 | Burns James William · Chief Legal Officer | Common stock | S — Open market or private sale | −3,280 | 34.71 | SEC filing |
| 2026-04-02 | Viswanadhan Krishnan · Chief Corp Dev & Strategy | Common stock | S — Open market or private sale | −2,959 | 34.71 | SEC filing |
| 2026-03-05 | Viswanadhan Krishnan · Chief Corp Dev & Strategy | Common stock | S — Open market or private sale | −2,959 | 27.80 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-18 | Foster-Cheek Kaye I · Director | Common stock | M — Exercise or conversion of derivative security | +2,816 | SEC filing |
| 2026-06-18 | Ballal Rahul D. · Director | Common stock | M — Exercise or conversion of derivative security | +2,816 | SEC filing |
| 2026-06-18 | CAPELLO JEFFREY D · Director | Restricted stock units | M — Exercise or conversion of derivative security | −2,816 | SEC filing |
| 2026-06-18 | Owen Adams Catherine · Director | Common stock | M — Exercise or conversion of derivative security | +2,816 | SEC filing |
| 2026-06-18 | Smith Cynthia · Director | Restricted stock units | M — Exercise or conversion of derivative security | −2,816 | SEC filing |
| 2026-06-18 | Jones Cecilia · Chief Financial Officer | Performance share units | M — Exercise or conversion of derivative security | −3,000 | SEC filing |
| 2026-06-18 | Ho Maykin · Director | Restricted stock units | M — Exercise or conversion of derivative security | −2,816 | SEC filing |
| 2026-06-18 | FOUSE JACQUALYN A · Director | Restricted stock units | M — Exercise or conversion of derivative security | −2,816 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.